Switzerland’s rise as the hub for life sciences startups is intrinsically linked to its growing ecosystem of biotech, medtech, and nanotech companies. This thriving ecosystem benefits from substantial investment in research and development, with the Swiss biotech sector marking a milestone with record R&D investments, approximately 3.6 billion dollars in recent years.
At Hoffmann & Partner AG, we are dedicated to supporting the financial management needs of these startups, providing bespoke CFO Services and Corporate Finance consulting. Our approach ensures startups navigate financial complexities with ease, enabling startups to concentrate on innovation and growth.
Uncover in the recent Life Science Review article how we support the biotech, medtech, and nanotech sectors successfully.